These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 21052077)

  • 1. Biomarkers in Alzheimer's disease drug development.
    Blennow K
    Nat Med; 2010 Nov; 16(11):1218-22. PubMed ID: 21052077
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Integrating ADNI results into Alzheimer's disease drug development programs.
    Cummings JL
    Neurobiol Aging; 2010 Aug; 31(8):1481-92. PubMed ID: 20447734
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biomarkers in Alzheimer's disease drug development.
    Cummings JL
    Alzheimers Dement; 2011 May; 7(3):e13-44. PubMed ID: 21550318
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Edinburgh Consensus: preparing for the advent of disease-modifying therapies for Alzheimer's disease.
    Ritchie CW; Russ TC; Banerjee S; Barber B; Boaden A; Fox NC; Holmes C; Isaacs JD; Leroi I; Lovestone S; Norton M; O'Brien J; Pearson J; Perry R; Pickett J; Waldman AD; Wong WL; Rossor MN; Burns A
    Alzheimers Res Ther; 2017 Oct; 9(1):85. PubMed ID: 29070066
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Translational medicine lessons from flurizan's failure in Alzheimer's disease (AD) trial: Implication for future drug discovery and development for AD.
    Wan HI; Jacobsen JS; Rutkowski JL; Feuerstein GZ
    Clin Transl Sci; 2009 Jun; 2(3):242-7. PubMed ID: 20443898
    [No Abstract]   [Full Text] [Related]  

  • 6. Alzheimer's disease biomarkers: their value in diagnosis and clinical trials.
    Small DH
    Front Biosci; 2002 Apr; 7():d986-8. PubMed ID: 11897567
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alzheimer's disease drug development: old problems require new priorities.
    Becker RE; Greig NH
    CNS Neurol Disord Drug Targets; 2008 Dec; 7(6):499-511. PubMed ID: 19128207
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The National Institute on Aging and the Alzheimer's Association Research Framework for Alzheimer's disease: Perspectives from the Research Roundtable.
    Knopman DS; Haeberlein SB; Carrillo MC; Hendrix JA; Kerchner G; Margolin R; Maruff P; Miller DS; Tong G; Tome MB; Murray ME; Nelson PT; Sano M; Mattsson N; Sultzer DL; Montine TJ; Jack CR; Kolb H; Petersen RC; Vemuri P; Canniere MZ; Schneider JA; Resnick SM; Romano G; van Harten AC; Wolk DA; Bain LJ; Siemers E
    Alzheimers Dement; 2018 Apr; 14(4):563-575. PubMed ID: 29653607
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Non human primate models for Alzheimer's disease-related research and drug discovery.
    Van Dam D; De Deyn PP
    Expert Opin Drug Discov; 2017 Feb; 12(2):187-200. PubMed ID: 27960560
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Searching for new pharmacological targets for the treatment of Alzheimer's disease in Down syndrome.
    Caraci F; Iulita MF; Pentz R; Flores Aguilar L; Orciani C; Barone C; Romano C; Drago F; Cuello AC
    Eur J Pharmacol; 2017 Dec; 817():7-19. PubMed ID: 28987272
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Down syndrome and Alzheimer's disease: Common pathways, common goals.
    Hartley D; Blumenthal T; Carrillo M; DiPaolo G; Esralew L; Gardiner K; Granholm AC; Iqbal K; Krams M; Lemere C; Lott I; Mobley W; Ness S; Nixon R; Potter H; Reeves R; Sabbagh M; Silverman W; Tycko B; Whitten M; Wisniewski T
    Alzheimers Dement; 2015 Jun; 11(6):700-9. PubMed ID: 25510383
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Measuring disease modification in Alzheimer's disease.
    Cummings JL
    CNS Spectr; 2007 Jan; 12(1 Suppl 1):11-4. PubMed ID: 17712916
    [No Abstract]   [Full Text] [Related]  

  • 13. Biomarkers for Alzheimer's disease: showing the way or leading us astray?
    Quinn JF
    J Alzheimers Dis; 2013; 33 Suppl 1(Suppl 1):S371-6. PubMed ID: 22766735
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel disease-modifying therapeutics for the treatment of Alzheimer's disease.
    Léger GC; Massoud F
    Expert Rev Clin Pharmacol; 2013 Jul; 6(4):423-42. PubMed ID: 23927670
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biological markers of amyloid beta-related mechanisms in Alzheimer's disease.
    Hampel H; Shen Y; Walsh DM; Aisen P; Shaw LM; Zetterberg H; Trojanowski JQ; Blennow K
    Exp Neurol; 2010 Jun; 223(2):334-46. PubMed ID: 19815015
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives.
    Hampel H; Frank R; Broich K; Teipel SJ; Katz RG; Hardy J; Herholz K; Bokde AL; Jessen F; Hoessler YC; Sanhai WR; Zetterberg H; Woodcock J; Blennow K
    Nat Rev Drug Discov; 2010 Jul; 9(7):560-74. PubMed ID: 20592748
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Are biomarkers harmful to recruitment and retention in Alzheimer's disease clinical trials? An international perspective.
    Hampel H; Prvulovic D
    J Nutr Health Aging; 2012 Apr; 16(4):346-8. PubMed ID: 22499455
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The medical and economic roles of pipeline pharmacogenetics: Alzheimer's disease as a model of efficacy and HLA-B(*)5701 as a model of safety.
    Roses AD
    Neuropsychopharmacology; 2009 Jan; 34(1):6-17. PubMed ID: 18923406
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hope builds for earlier detection of Alzheimer's disease.
    Opar A
    Nat Rev Drug Discov; 2010 Aug; 9(8):579-81. PubMed ID: 20671750
    [No Abstract]   [Full Text] [Related]  

  • 20. Clinical trials for early (pre-dementia) Alzheimer's disease: a case for mild cognitive impairment.
    Petersen RC
    J Nutr Health Aging; 2010 Apr; 14(4):304-5. PubMed ID: 20306001
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.